Affiliation:
1. The First Affiliated Hospital of USTC, University of Science and Technology of China
Abstract
Abstract
Targeted therapy for lung cancer research has advanced quickly in recent years, particularly EGFR-TKIs in the grouping of EGFR-mutant lung cancer, however clinical treatment has encountered difficulties with acquired drug resistance. Due to their great specificity, few adverse reactions, and prolonged tumor control duration, immune checkpoint inhibitors PD-1 and PD-L1 antibodies have emerged as a new therapy approach for NSCLC with the advancement of tumor biology. AXL, a gene that codes for receptor tyrosine kinases, has been linked to the growth, treatment resistance, and immunological imbalance of cancer cells. Its protein has been found to be abnormally expressed in NSCLC cancer tissues. Our study shows a positive regulatory link between AXL and PD-L1 expression, and AXL can upregulate PD-L1 to facilitate the development of acquired drug resistance in EGFR-mutant lung cancer treated with gefitinib. We offer additional understandings for AXL to overcome the gefitinib resistance mechanism in NSCLC, while also providing ideas for addressing targeted therapy resistance.
Publisher
Research Square Platform LLC
Reference32 articles.
1. GREENHALGH J, BOLAND A, BATES V et al. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer [J].Cochrane Database Syst Rev, 2021,3.
2. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer [J];SORIA JC;N Engl J Med,2018
3. SIM E H, YANG I A, WOOD-BAKER R et al. Gefitinib for advanced non-small cell lung cancer [J].Cochrane Database Syst Rev, 2018,1.
4. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer [J];TAN C S, CHO B C, SOO RA;Lung Cancer,2016
5. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer [J];ZHANG K;J Cancer Res Ther,2016